PK-PD of combination antituberculosis therapy for suppression of drug-resistance

联合抗结核治疗抑制耐药性的PK-PD

• 批准号: 7635777
• 负责人: Tawanda Gumbo
• 金额: $ 62.83万
• 依托单位: UT SOUTHWESTERN MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-06-15 至 2012-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7635777
• 关键词: Adherence; Antibiotics; Antitubercular Agents; Bacillus (bacterium); Chronic; Ciprofloxacin; Clinical; Combination Drug Therapy; Combined Modality Therapy; Communicable Diseases; Communities; Data; Development; Dose; Drug Combinations; Drug Kinetics; Drug Resistant Tuberculosis; Drug resistance; Extreme drug resistant tuberculosis; Face; Goals; Human; Hypoxia; In Vitro; Infection; International; Lead; Life; Methods; Modeling; Moxifloxacin; Multi-Drug Resistance; Multidrug-Resistant Tuberculosis; Mutation; Mycobacterium tuberculosis; Outcome; Patients; Pharmaceutical Preparations; Pharmacodynamics; Population; Prevalence; Prevention; Public Health; Pyrazinamide; Resistance; Rifampin; Schedule; Science; Solutions; Staging; Testing; Therapeutic; Time; Translating; Translations; Treatment Protocols; Tuberculosis; Virulent; Work; bactericide; base; chemotherapy; design; effective therapy; in vitro Model; innovation; isoniazid; man; mutant; non-compliance; pharmacodynamic model; response; simulation; success; tuberculosis drugs; tuberculosis treatment

DESCRIPTION (provided by applicant): Tuberculosis (TB) is one of the most important killers of all time. First-line therapy, which consists of combination of rifampin, isoniazid, and pyrazinamide, is under threat from the development of multi-drug resistant TB (MDR-TB) and extensively drug resistant TB. The drug resistance is driven, to a great extent, by poor compliance. It is hypothesized that resistance emerges due to the pharmacokinetic mismatch of component drugs, effective monotherapy of bacilli under acidic and hypoxic conditions, differential post-antibiotic effects of drugs, and prolonged time in the mutant selection window (TMSW). We will test these hypotheses using pharmacokinetic-pharmacodynamic (PK-PD) methods. We have developed an in vitro PKPD model of TB which we have used to study resistance emergence to rifampin and isoniazid monotherapy during bactericidal activity. PK-PD studies of resistance emergence during sterilizing activity had as of yet not been performed. In the current application, we present PK-PD data on pyrazinamide sterilizing activity, setting the stage to study the PK-PD of combination anti-TB drugs during both bactericidal and sterilizing activity. Our long term goal is to develop anti-TB therapy dosing strategies that will lead to suppression of MDR-TB. The objective of the current application is to use the in vitro PK-PD model of TB to expose Mycobacterium tuberculosis to anti-TB drug pharmacokinetics similar to those encountered in humans. Our central hypothesis is that PK-PD optimization of combination anti-TB regimens will lead suppression of MDR-TB. We will test the hypothesis and achieve our objectives by examining four specific aims. (1) We will apply PK-PD methods to test the pharmacokinetic mismatch-, the effective monotherapy-, and the TMSW- hypothesis. (2) We will identify the exposures of first line anti-TB drug combination therapy that are associated with suppression of resistance during both bactericidal and sterilizing therapy. (3) We will identify the degree of poor compliance associated with emergence of resistance and identify PK-PD solutions to reduce emergence of MDR-TB, despite the poor compliance. We will also identify the order of emergence of chromosomal mutations that confer drug resistance during non-compliance. (4) We will translate the in vitro PK-PD exposures and strategies that suppress resistance to human therapy by use of Monte Carlo simulations. We will examine 2-drug and 3-drug combinations during both bactericidal and sterilizing activity in the in vitro model, and examine the size of resistant sub-populations that arise with each particular dosing strategy. Our in vitro model uses virulent M. tuberculosis and mimics the concentration-time profile of drugs encountered in TB patients. From the proposed studies, we expect some of the standard explanations on how resistance arises to be false, which will lead to fundamental changes in strategies to reduce MDR-TB. Since poor compliance is a fact of clinical life, dosing strategies that suppress drug resistance despite poor compliance would be a major therapeutic innovation. Tuberculosis is a global problem that has been declared a global emergence by the international community. A particularly big problem is the emergence of multidrug resistant tuberculosis. The current application will apply pharmacokinetic-pharmacodynamic solutions to this public health problem.

描述（由申请人提供）：结核病（TB）是有史以来最重要的杀手之一。由利福平、异烟肼和吡嗪酰胺组合组成的一线治疗受到多药耐药结核病（MDR-TB）和广泛耐药结核病发展的威胁。耐药性在很大程度上是由依从性差造成的。据推测，耐药性的出现是由于组分药物的药代动力学不匹配，在酸性和缺氧条件下的有效单一治疗，药物的不同抗生素后效应，以及在突变体选择窗口（TMSW）中的时间延长。我们将使用药代动力学-药效学（PK-PD）方法检验这些假设。我们已经开发了一种体外结核病PKPD模型，我们已经使用该模型来研究在杀菌活性期间对利福平和异烟肼单药治疗的耐药性出现。尚未进行灭菌活动期间出现抗性的PK-PD研究。在本申请中，我们提供了吡嗪酰胺杀菌活性的PK-PD数据，为研究联合抗结核药物在杀菌和杀菌活性期间的PK-PD奠定了基础。我们的长期目标是开发抗结核治疗剂量策略，从而抑制耐多药结核病。本申请的目的是使用TB的体外PK-PD模型将结核分枝杆菌暴露于与人类中遇到的那些类似的抗TB药物药代动力学。我们的中心假设是，联合抗结核治疗方案的PK-PD优化将导致MDR-TB的抑制。我们将检验假设，并通过检查四个具体目标来实现我们的目标。(1)我们将应用PK-PD方法来检验药代动力学不匹配、有效的单药治疗和TMSW假设。(2)我们将确定一线抗结核药物联合治疗与杀菌和消毒治疗期间耐药性抑制相关的暴露。(3)我们将确定与耐药性出现相关的依从性差的程度，并确定PK-PD解决方案，以减少MDR-TB的出现，尽管依从性差。我们还将确定染色体突变的出现顺序，在不遵守期间赋予耐药性。(4)我们将翻译体外PK-PD暴露和策略，通过使用Monte Carlo模拟来抑制对人类治疗的耐药性。我们将在体外模型中检查2种药物和3种药物组合的杀菌和灭菌活性，并检查每种特定给药策略产生的耐药亚群的大小。我们的体外模型使用毒性M。结核病和模仿的浓度-时间曲线的药物中遇到的结核病患者。从拟议的研究中，我们预计关于耐药性如何产生的一些标准解释是错误的，这将导致减少耐多药结核病战略的根本变化。由于依从性差是临床生活的事实，因此尽管依从性差但抑制耐药性的给药策略将是主要的治疗创新。结核病是一个全球性问题，国际社会已宣布这是一个全球性问题。一个特别大的问题是耐多药结核病的出现。本申请将药代动力学-药效学解决方案应用于这一公共卫生问题。